LISTS OF FIGURES

Figure 1
Estimated new cases and deaths in the US for the top 10 leading cancers by sex

Figure 2
The ERBB receptor family of proteins with the known ligands

Figure 3
Chemical structure of Erlotinib

Figure 4
Summary of all known mutations that confer resistance or sensitivity in lung adenocarcinomas

Figure 5
MS spectra showing incorporation of amino acids by SILAC method

Figure 6
Pipeline of experimental strategy followed for labeling, treatment and validation.

Figure 7
4G10 Immunoprecipitation of H3255 cells treated with EGF and Erlotinib

Figure 8
Distribution of peptides identified in this study with respective behavior on treatment with EGF and Erlotinib

Figure 9
Enrichment of molecules in canonical pathways from IPA analysis of tyrosine phosphorylated peptides

Figure 10
Enrichment of molecules in canonical pathways from IPA analysis of serine/threonine phosphorylated peptides

Figure 11
Enrichment of molecules in canonical pathways from IPA analysis of peptides are activated or remain unchanged on EGF but are dephosphorylated on Erlotinib treatment.
Figure 12
Phosphorylation status of ERBB family of proteins

Figure 13
Western blot and phospho RTK analyses phosphorylation sites S473 on AKT1, T202/Y204 in ERK1 and S2248 in mTOR

Figure 14
MS and MS/MS spectra of sites Y204 and T202 identified from mass spectrometric analyses of MAPK3

Figure 15
mTOR phospho map indicating all identified phosphorylation sites and their behavior that were identified in the mass spectrometric analysis.

Figure 16
Phosphorylation status of VEGFR receptors observed using phospho RTK arrays

Figure 17
Phosphorylation status of FGFR receptors observed using phospho RTK arrays

Figure 18
Phosphorylation status of Ephrin family of receptors observed using phospho RTK arrays

Figure 19
Phosphorylation status of receptor tyrosine kinases observed using phospho RTK arrays

Figure 20
MS and MS/MS spectra showing change in phosphorylation of SCAMP1, ERBB2IP, PKP4 and MSTIR.

Figure 21
MS and MS/MS spectra showing change in phosphorylation of CBL, DAPP1 and CTNNB1.

Figure 22
Phospho map indicating all phosphorylation sites of signaling molecules identified with modulation on EGF and Erlotinib.

Appendix Figure A
Signaling pathway map of the EGFR pathway